Want to see HK:8225 full AI Analyst Report?
8225 Stock Chart & Stats
HK$0.14
<HK$0.01(2.58%)
At close: 4:00 PM EST
HK$0.14
<HK$0.01(2.58%)
Day’s Range― - ―
52-Week RangeHK$0.08 - HK$0.20
Previous CloseN/A
Volume40.00K
Average Volume (3M)266.67K
Market Cap
HK$79.63M
Enterprise ValueHK$116.60
Total Cash (Recent Filing)HK$25.16M
Total Debt (Recent Filing)HK$0.00
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding995,351,700
10 Day Avg. Volume154,000
30 Day Avg. Volume266,666
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.36
Price to Sales (P/S)4.69
P/FCF Ratio14.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA zero-debt capital structure materially reduces solvency and interest-cost risk, giving management flexibility to fund operations, R&D or marketing from internal cash or equity. Over 2–6 months this supports resilience during cyclical pressure and lowers refinancing risk.
Improved Cash GenerationSustained positive operating and recent free cash flow indicate the core business can generate cash despite accounting losses. This durable cash-generation ability reduces reliance on external financing and supports operational continuity and selective reinvestment over the medium term.
Higher Gross MarginsA substantial gross-margin uplift suggests improved product mix, pricing power, or lower COGS. If maintained, higher gross margins can form the basis for future operating margin recovery once fixed costs are controlled, improving long-term profitability potential.
Bears Say
Persistent Multi-Year LossesLarge, sustained losses erode operational viability and reduce room for strategic investment. Over several quarters this weakens competitive positioning, strains management bandwidth on cost cuts instead of growth, and risks further capital dilution if external funding is required.
Eroding Equity And Negative ROEMaterial equity erosion and negative ROE reflect persistent profitability shortfalls that shrink the capital base. Structurally this limits ability to finance growth internally, raises the probability of future equity raises, and can impair supplier/customer confidence over the medium term.
Volatile Free Cash FlowSharp declines and historical volatility in free cash flow undermine planning and strategic investment. Persistent variability increases the chance management must curtail capex or seek external funding, reducing long-term execution credibility and raising financing costs or dilution risk.
8225 FAQ
What was China Health Group Inc.’s price range in the past 12 months?
China Health Group Inc. lowest stock price was HK$0.08 and its highest was HK$0.20 in the past 12 months.
What is China Health Group Inc.’s market cap?
China Health Group Inc.’s market cap is HK$79.63M.
When is China Health Group Inc.’s upcoming earnings report date?
China Health Group Inc.’s upcoming earnings report date is Mar 30, 2027 which is in 231 days.
How were China Health Group Inc.’s earnings last quarter?
Currently, no data Available
Is China Health Group Inc. overvalued?
According to Wall Street analysts China Health Group Inc.’s price is currently Overvalued.
Does China Health Group Inc. pay dividends?
China Health Group Inc. does not currently pay dividends.
What is China Health Group Inc.’s EPS estimate?
China Health Group Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Health Group Inc. have?
China Health Group Inc. has 995,351,700 shares outstanding.
What happened to China Health Group Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of China Health Group Inc.?
Currently, no hedge funds are holding shares in HK:8225
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
China Health Group Inc.
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research and promotion, rehabilitation tourism, and specialty hospital services, as well as Wanquan cloud health services. In addition, the company offers pharmacodynamics and clinical research of drugs. China Health Group Inc. was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. The company was founded in 1998 and is headquartered in Beijing, China.
Technical Analysis
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Mega Genomics Limited
―
Biosino Bio-Technology & Science, Inc. Class H
―